Ridgewood Investments LLC bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 55 shares of the company’s stock, valued at approximately $28,000.
A number of other hedge funds have also added to or reduced their stakes in IDXX. Victory Capital Management Inc. boosted its position in shares of IDEXX Laboratories by 6.1% in the fourth quarter. Victory Capital Management Inc. now owns 149,385 shares of the company’s stock valued at $60,943,000 after acquiring an additional 8,595 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in IDEXX Laboratories by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 446,371 shares of the company’s stock valued at $182,102,000 after purchasing an additional 12,904 shares during the period. Fifth Third Bancorp grew its position in shares of IDEXX Laboratories by 18.1% during the 1st quarter. Fifth Third Bancorp now owns 13,535 shares of the company’s stock valued at $6,769,000 after purchasing an additional 2,076 shares in the last quarter. Crossmark Global Holdings Inc. increased its holdings in shares of IDEXX Laboratories by 11.0% in the fourth quarter. Crossmark Global Holdings Inc. now owns 5,080 shares of the company’s stock worth $2,072,000 after purchasing an additional 505 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in shares of IDEXX Laboratories by 2.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,963 shares of the company’s stock worth $4,065,000 after buying an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 86.53% of the company’s stock.
Insider Activity at IDEXX Laboratories
In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 2,187 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $469.02, for a total value of $1,025,746.74. Following the completion of the sale, the director now owns 872 shares in the company, valued at $408,985.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Jonathan W. Ayers sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $489.23, for a total transaction of $4,892,300.00. Following the completion of the transaction, the director now owns 137,039 shares in the company, valued at $67,043,589.97. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 2,187 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $469.02, for a total transaction of $1,025,746.74. Following the transaction, the director now directly owns 872 shares in the company, valued at $408,985.44. The disclosure for this sale can be found here. Insiders sold 13,187 shares of company stock worth $6,402,047 in the last ninety days. 2.11% of the stock is owned by company insiders.
IDEXX Laboratories Price Performance
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 2nd. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.38 by $0.17. The firm had revenue of $900.20 million for the quarter, compared to the consensus estimate of $887.36 million. IDEXX Laboratories had a net margin of 20.38% and a return on equity of 117.37%. Equities analysts predict that IDEXX Laboratories, Inc. will post 9.65 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on IDXX shares. StockNews.com started coverage on IDEXX Laboratories in a research report on Thursday, May 18th. They set a “buy” rating for the company. Morgan Stanley boosted their price objective on IDEXX Laboratories from $543.00 to $590.00 and gave the stock an “overweight” rating in a report on Thursday, March 23rd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $527.86.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
- Five stocks we like better than IDEXX Laboratories
- How to Invest for Retirement at Age 60
- Guide to Early Retirement: How to Invest for Early Retirement
- How to Invest in Cryptocurrency for Beginners
- How to Invest for Retirement at Age 50
- How to Analyze a Stock: A Step-by-Step Guide
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
